Quince Therapeutics
QNCX
48 hedge funds and large institutions have $3.44M invested in Quince Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 23 reducing their positions, and 18 closing their positions.
217% more call options, than puts
Call options by funds: $228K | Put options by funds: $72K
0.05% less ownership
Funds ownership: 0.13% → 0.07% (-0.05%)
17% less funds holding
Funds holding: 58 → 48 (-10)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
72% less capital invested
Capital invested by funds: $12.4M → $3.44M (-$8.95M)
87% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$115K |
| 2 |
E
Ergoteles
New York
|
+$32.8K |
| 3 |
TLP
Tri Locum Partners
New York
|
+$18.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
| 5 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$9.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$836K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$650K |
| 3 |
PHAM
Pacific Heights Asset Management
San Francisco,
California
|
-$432K |
| 4 |
BC
Burleson & Co
Petaluma,
California
|
-$247K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$221K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
51
PDT Partners
New York
| – | -$61K | -230 | Closed |
|
|
OQS
52
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$48K | -181 | Closed |
|
|
IC
53
Iconiq Capital
San Francisco,
California
| – | -$41K | -155 | Closed |
|
54
Goldman Sachs
New York
| – | -$39K | -148 | Closed |
|
|
SSA
55
Schonfeld Strategic Advisors
New York
| – | -$36K | -137 | Closed |
|
56
Allspring Global Investments
Charlotte,
North Carolina
| – | -$28K | -107 | Closed |
|
57
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$23K | -86 | Closed |
|
|
SW
58
SVB Wealth
Boston,
Massachusetts
| – | -$20K | -75 | Closed |
|
59
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$18K | -68 | Closed |
|
|
PCM
60
Prelude Capital Management
New York
| – | -$14K | -51 | Closed |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | -$11K | -41 | Closed |
|
62
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | -15 | Closed |
|
|
ACM
63
Aquatic Capital Management
Chicago,
Illinois
| – | -$3K | -11 | Closed |
|
QNCX Hedge Fund Activity: Q4 2022 in Review
48 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q4 2022, worth a combined $3.44M — down 72% from $12.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of QNCX and 8 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, adding an estimated $115K. The largest seller was EPIQ Capital Group, cutting an estimated $836K.
- 48 institutional investors held Quince Therapeutics (QNCX) as of Q4 2022, down from 58 in Q3 2022.
- Funds reported $3.44M of Quince Therapeutics stock for Q4 2022, down 72% quarter-over-quarter.
- 8 funds opened new Quince Therapeutics positions in Q4 2022 and 18 closed out, a net change of -10 holders.
- The largest Quince Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $115K added.
- The largest Quince Therapeutics seller in Q4 2022 was EPIQ Capital Group, an estimated $836K sold.
Based on aggregated 13F filings for Q4 2022.